Biotech Firm to Present at Psychedelic Therapeutics Conference in New Orleans
Why are current treatments for neurodegenerative diseases often limited to symptom management? Five Discovery, a biotechnology company, is addressing this gap by developing small-molecule therapeutics to repair dysfunctional brain circuits. Based in the emerging field of Regenerative Neurology, Five Discovery aims to stabilize and restore neural circuits without the hallucinogenic effects of traditional psychedelics.
Five Discovery will introduce itself at the Psychedelic Therapeutics and Drug Development Conference in New Orleans, Louisiana, on February 26–27, 2026. CEO Dr. Manesh Girn will present on February 26 at 3:30 p.m. with a talk titled “Beyond Mood Disorders: Reframing Non-Hallucinogenic Psychedelics as Neuroregenerative Therapeutics.”Neurodegenerative disorders are fundamentally disorders of circuit dysfunction,” said Dr. Manesh Girn, Co-Founder and CEO of Five Discovery. “Our objective is to translate the well-characterized plasticity biology of rapid-acting serotonergic therapeutics into small-molecule medicines that stabilize and restore dysfunctional neural circuits, without the hallucinogenic effects that limit psychedelic therapies.”
Key Insights at a Glance
- Regenerative Neurology: An emerging therapeutic discipline focused on restoring and stabilizing dysfunctional neural circuits.
- Non-Hallucinogenic Neuroplastogens: Small molecules inspired by 5-MeO-DMT biology, designed to preserve neuroplastic and anti-inflammatory effects.
- Lead Program: Targets Levodopa-Induced Dyskinesia (LID), a significant unmet clinical need in Parkinson’s disease.
- Clinical Validation: Establishes a foundation for future development in broader Parkinson’s Disease and additional CNS disorders.
Why Current Treatments Fall Short
Current treatments for neurodegenerative diseases often focus on managing symptoms rather than addressing the underlying circuit dysfunction. This approach leaves a significant gap in therapeutic options, particularly for conditions like Levodopa-Induced Dyskinesia (LID), a debilitating complication of long-term levodopa therapy in Parkinson’s disease. The lack of effective treatments for such conditions highlights the urgent need for innovative solutions that can stabilize and restore neural circuits. Five Discovery’s approach offers a promising path forward, with the potential to transform the landscape of neurodegenerative disease management.
The Clock Is Ticking on Neurodegenerative Solutions
Just as a ticking clock signals the urgency of time, Five Discovery is racing against the clock to develop effective treatments for neurodegenerative diseases. The company’s lead program targeting LID is a strategic entry point, with eligibility for orphan-drug designation and FDA-validated endpoints. This focused approach not only accelerates clinical validation but also sets the stage for broader applications in Parkinson’s Disease and other central nervous system disorders. The next critical step is the presentation at the Psychedelic Therapeutics and Drug Development Conference, where Five Discovery will share its groundbreaking research and vision.
Five Discovery Mobilizes for Neuroregenerative Therapeutics
Five Discovery is advancing Regenerative Neurology, an emerging therapeutic discipline focused on restoring and stabilizing dysfunctional neural circuits. The company’s lead program targets Levodopa-Induced Dyskinesia (LID), a debilitating complication of long-term levodopa therapy in Parkinson’s disease. By leveraging non-hallucinogenic neuroplastogens inspired by 5-MeO-DMT biology, Five Discovery aims to preserve the validated neuroplastic and anti-inflammatory effects of serotonergic psychedelics while eliminating hallucinogenic activity. This approach enables scalable clinical development and positions the company to address significant unmet clinical needs. Clinical validation in LID will establish a foundation for future development in broader Parkinson’s Disease and additional CNS disorders.
Future Outlook
Five Discovery is like a skilled surgeon, meticulously repairing the intricate neural circuits that are essential for brain function. By focusing on LID, the company is laying the groundwork for broader applications in neurodegenerative diseases. The upcoming presentation at the Psychedelic Therapeutics and Drug Development Conference marks a critical milestone, setting the stage for further clinical trials and regulatory milestones. The company’s strategic approach and innovative technology position it to make significant strides in the field of regenerative neurology.
Conclusion
The launch of Five Discovery marks a significant step forward in the treatment of neurodegenerative diseases. By focusing on repairing dysfunctional brain circuits, the company is addressing a critical unmet need and setting the stage for broader applications. Five Discovery’s innovative approach and strategic focus on LID highlight its potential to transform the landscape of neurodegenerative disease management. Join the conversation in the comments below.
About Five Discovery
Five Discovery is a regenerative neurology biotechnology company developing non-hallucinogenic neuroplastogens inspired by 5-MeO-DMT biology. The company’s small-molecule portfolio is designed to restore and stabilize dysfunctional neural circuits in neurodegenerative disease and brain injury. Its lead program targets Levodopa-Induced Dyskinesia, with planned expansion into Parkinson’s Disease and broader central nervous system indications.
Source link: https://www.businesswire.com/
